Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R. Wilson, Fiona Miall, Marie‐Pierre Moles‐Moreau et al.|UCL Discovery (University College London)|2022Cited by 76
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Andrés J.M. Ferreri, Christopher P. Fox et al.|British Journal of Haematology|2020Cited by 69
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP deliveryMatthew R. Wilson, Pam McKay, Toby A. Eyre et al.|Blood Advances|2020Cited by 54
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H. Russell, Shankara Paneesha, Charlotte S. Wilhelm-Benartzi et al.|Journal of Clinical Oncology|2024Cited by 40
Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trialZulfa Omer, Wojciech Jurczak, Alexey V. Danilov et al.|Blood|2025Cited by 3